Durvalumab (Imfinzi) + Tremelimumab
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Muscle-invasive Bladder Cancer
Conditions
Muscle-invasive Bladder Cancer
Trial Timeline
Jul 15, 2018 → May 18, 2020
NCT ID
NCT03234153About Durvalumab (Imfinzi) + Tremelimumab
Durvalumab (Imfinzi) + Tremelimumab is a phase 2 stage product being developed by AstraZeneca for Muscle-invasive Bladder Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT03234153. Target conditions include Muscle-invasive Bladder Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03234153 | Phase 2 | Terminated |
Competing Products
12 competing products in Muscle-invasive Bladder Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Enfortumab Vedotin | Astellas Pharma | Phase 3 | 77 |
| Durvalumab (MEDI4736) + Bacillus Calmette-Guerin (BCG) | AstraZeneca | Phase 3 | 77 |
| Pembrolizumab + Gemcitabine | Merck | Phase 2 | 52 |
| Chemotherapy + Immunotherapy Induction + Immunotherapy Maintenance | Merck | Phase 2 | 52 |
| Autogene Cevumeran + Nivolumab + Saline | Roche | Phase 2 | 52 |
| Atezolizumab | Roche | Phase 3 | 77 |
| Nivolumab + Nab-paclitaxel + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cretostimogene Grenadenorepvec | CG Oncology | Phase 2 | 49 |
| CG0070 + Nivolumab | CG Oncology | Phase 1 | 30 |
| AU-011 | Aura Biosciences | Phase 1 | 25 |
| REOLYSIN® + Gemcitabine + Cisplatin | Oncolytics Biotech | Phase 1 | 25 |